Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.27 Consensus Target Price from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $19.4545.

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group raised Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals in a report on Friday, June 12th. They set a “buy” rating and a $14.00 target price on the stock. Finally, Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th.

Oric Pharmaceuticals Stock Up 0.1%

ORIC stock opened at $13.75 on Monday. The firm has a market capitalization of $1.43 billion, a P/E ratio of -10.19 and a beta of 1.02. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93. The company has a fifty day simple moving average of $10.48 and a two-hundred day simple moving average of $10.49.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, analysts anticipate that Oric Pharmaceuticals will post -1.53 EPS for the current year.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $27 target, implying considerable potential upside if Oric’s clinical pipeline and future commercial prospects develop as expected.
• Neutral Sentiment: HC Wainwright issued new 2027 forecasts, projecting losses of $0.43 per share in Q1, $0.45 in Q2, $0.47 in Q3 and $0.49 in Q4, for a full-year loss of $1.85 per share. The estimates indicate that the company is expected to remain unprofitable through 2027.
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the figures show no measurable short positioning and appear internally inconsistent, they provide little useful indication of trading pressure.
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a $0.40 loss from $0.36, cut its Q4 estimate to a $0.42 loss from $0.37, and lowered its FY2026 forecast to a $1.54 loss from $1.41. These revisions point to higher expected near-term spending or weaker financial performance.

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Oric Pharmaceuticals during the 2nd quarter valued at $73,904,000. Orbimed Advisors LLC increased its holdings in shares of Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after acquiring an additional 2,742,475 shares during the period. Paradigm Biocapital Advisors LP bought a new position in shares of Oric Pharmaceuticals in the 4th quarter worth $19,642,000. Siren L.L.C. raised its position in shares of Oric Pharmaceuticals by 197.6% in the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after acquiring an additional 1,990,617 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Oric Pharmaceuticals by 77.1% during the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after purchasing an additional 1,854,458 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.